A study due to be presented at the 2026 Annual Meeting of The Menopause Society suggests an awkward truth about menopause care may be easier to solve than the symptoms themselves: many women cannot easily get to the therapies that already help.
The intervention in question is not a new drug. Researchers at Cedars-Sinai and collaborators tested an AI-enhanced virtual reality program, MenoZen VR, designed to deliver elements of cognitive behavioral therapy and related support through a headset. Participants used a Meta Quest 3S and were guided by an AI avatar called Maia through modules that included CBT-based strategies, mindfulness, paced breathing, psychoeducation and talk-therapy-style prompts.
What the researchers are reporting, at this stage, is not proof that the program reduces hot flashes or improves sleep better than standard care. The study described by Medical Xpress was small, multicenter and qualitative. It focused on feasibility and acceptability: whether midlife women would use a menopause-specific VR tool and find it relevant enough to imagine it as part of care.
That matters because CBT is already an established non-drug option for several menopause symptoms, including hot flashes, insomnia, low mood and sexual difficulties. The problem is access. A treatment can be evidence-based and still remain far away in the ordinary sense of the word — too expensive, too scarce, too inconvenient, too difficult to fit around work, care or the plain exhaustion that symptoms bring.
The study recruited women aged 45 to 60 who reported bothersome hot flashes, defined here as more than 28 episodes a week, and who were not using hormone therapy. According to the report, the findings suggest strong interest in a personalized, nonpharmacologic tool built specifically for menopause symptom management.
That is a narrower result than a headline about AI and virtual reality can make it sound. Interest is not the same as clinical benefit. A guided avatar may feel private and convenient; it may also fail to help when tested more rigorously against existing therapy, self-help materials or no treatment at all. Conference presentations are also an early stage of scientific reporting, before the fuller scrutiny that usually comes with a complete published paper.
Still, this is a more serious use of health technology than the usual spray of wellness gimmicks. Menopause is often discussed as if women must choose between medication, stoicism and internet folklore. In reality, evidence-based behavioral care exists, and one reason it goes underused is that health systems do a poor job of placing it within reach.
Hormone therapy remains the gold-standard drug treatment for many women, but Medical Xpress reports U.S. use was 1.7% in 2023. Some women cannot or do not want to use hormones; others may want non-drug support alongside them. A tool that expands access to CBT would not replace clinicians, and the study does not show that it can. It does, however, point to a practical question medicine often neglects: if something works, can people actually get it?
For menopause care, that question may be at least as important as the headset.
Marcus Azzopardi 
Ryan C